Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bromocriptine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 7/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromocriptine SCHEMBL186901 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL29414631 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL29364057 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL8032620 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL19276395 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL9526627 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL23468147 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL3134317 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL25297 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL11890530 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9492410-B2 | Methods for treatment of Parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-11-15 | — | — | US | disclosed |
| US-20150150833-A1 | Methods For Treatment of Parkinson's Disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-04 | — | — | US | disclosed |
| US-8901176-B2 | Methods for treatment of Parkinson's disease | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2014-12-02 | — | — | US | disclosed |
| US-8877755-B2 | Dopamine-agonist combination therapy for improving sleep quality | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2070526-B1 | Methods for treatment of Parkinson's disease | NEWRON PHARM SPA (IT) | 2014-02-26 | — | — | EP | disclosed |
| US-20130053368-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-02-28 | — | — | US | disclosed |
| US-8283380-B2 | Methods for treatment of parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-10-09 | — | — | US | disclosed |
| US-20100004251-A1 | Dopamine-Agonist Combination Therapy For Improving Sleep Quality | SEPRACOR INC. (US) | 2010-01-07 | — | — | US | disclosed |
| EP-1613296-B1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARM SPA (IT) | 2009-07-01 | — | — | EP | disclosed |
| EP-2070526-A1 | \"Methods for treatment of Parkinson's disease\ | Newron Pharmaceuticals S.p.A. (IT) | 2009-06-17 | — | — | EP | disclosed |
| US-20030013692-A1 | Methods of treating neurological disorders | GULLANS STEVEN R (US) | 2003-01-16 | — | — | US | disclosed |
| WO-2002056892-A2 | METHODS OF TREATING NEUROLOGICAL DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053368-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | MAOB, MAOA, SNCA | DRD3 222/4885DRD2 52/4885DRD4 154/4885 |
| US-20100004251-A1 | Dopamine-Agonist Combination Therapy For Improving Sleep Quality | DRD2, DRD1, DRD3 | DRD3 3/4885DRD2 1/4885DRD4 10/4885 |
| US-20150150833-A1 | Methods For Treatment of Parkinson's Disease | MAOB, MAOA, SNCA | DRD3 222/4885DRD2 52/4885DRD4 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.